ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,586.89
      -0.83%
      US Tech 100
      19,636.50
      -2.40%
      Dow Jones
      39,786.43
      0.16%
      Brent Oil
      85.055
      0.01%
      Bitcoin
      57,998.78
      0.41%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU
      6. Sanofi (SAN)

      7. Sanofi (SAN) News

      SAN

      Sanofi (SAN)

      Sanofi
      		Date:
      Sort by:
       Showing the most relevant articles for your search:EU:SAN
      DateTimeSourceHeadlineSymbolCompany
      12:21PMiHub NewswireFeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing
      01/17/20244:57PMGlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares - December 2023EU:SANSanofi
      01/16/20245:08AMDow Jones NewsECHO BOURSE: Sanofi relevé de "neutre" à "acheter" par UBSEU:SANSanofi
      01/09/20242:14AMDow Jones NewsSanofi Names Brian Foard Head of Specialty-Care UnitEU:SANSanofi
      01/09/20242:04AMDow Jones NewsSanofi nomme Brian Foard responsable de l'entité Médecine de spécialitésEU:SANSanofi
      01/09/20241:59AMDow Jones NewsSanofi nomme Brian Foard responsable de l'entité Médecine de spécialitésEU:SANSanofi
      01/09/20241:30AMGlobeNewswire Inc.Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive CommitteeEU:SANSanofi
      01/09/20241:30AMGlobeNewswire Inc.Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive CommitteeEU:SANSanofi
      01/09/20241:30AMGlobeNewswire Inc.Communiqué de presse : Brian Foard est nommé Responsable de l’entité Médecine de Spécialités, membre du Comité exécutif de SanofiEU:SANSanofi
      01/08/202411:10AMDow Jones NewsECHO BOURSE: Sanofi bénéficiera encore en 2024 du succès du Dupixent - BarclaysEU:SANSanofi
      01/08/20246:50AMMF Dow Jones (Italiano)Merck, Roche e Sanofi vedono spazio per fusioni e acquisizioni nel 2024-- Market TalkEU:SANSanofi
      01/08/20244:16AMDow Jones NewsLe retour des IPO pourrait animer les marchés de capitaux en 2024 - DJ PlusEU:SANSanofi
      01/08/20244:04AMDow Jones NewsECHO BOURSE: Merck, Roche et Sanofi devraient réaliser des achats en 2024 - BerenbergEU:SANSanofi
      01/02/20243:32AMDow Jones NewsLe Beyfortus de Sanofi et AstraZeneca approuvé en Chine contre le VRSEU:SANSanofi
      01/02/20243:27AMDow Jones NewsLe Beyfortus de Sanofi et AstraZeneca approuvé en Chine contre le VRSEU:SANSanofi
      12/21/20232:25AMDow Jones NewsSanofi Ends Drug Program After Late-Stage Trial in Lung Cancer FailsEU:SANSanofi
      12/21/20232:22AMDow Jones NewsSanofi abandonne le développement clinique de l'anticancéreux tusamitamab ravtansineEU:SANSanofi
      12/21/20232:17AMDow Jones NewsSanofi abandonne le développement clinique de l'anticancéreux tusamitamab ravtansineEU:SANSanofi
      12/21/20231:30AMGlobeNewswire Inc.Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpointEU:SANSanofi
      12/21/20231:30AMGlobeNewswire Inc.Communiqué de presse : Sanofi annonce la fin du programme évaluant le tusamitamab ravtansine après qu’un essai de phase III dans le traitement de 2èmeligne du CBNPC n’a pas atteint son critère d’évaluation primaire EU:SANSanofi
      12/21/20231:30AMGlobeNewswire Inc.Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpointEU:SANSanofi
      12/19/20237:38AMMF Dow Jones (Italiano)Le azioni di Innate Pharma salgono dopo l'esercizio dell'opzione dilicenza da parte di SanofiEU:SANSanofi
      12/19/20237:28AMDow Jones NewsInnate Pharma Shares Rise after Sanofi Exercises Licensing OptionEU:SANSanofi
      12/19/20232:39AMDow Jones NewsSanofi exerce une option de licence en oncologie auprès d'Innate PharmaEU:SANSanofi
      12/19/20232:34AMDow Jones NewsSanofi exerce une option de licence en oncologie auprès d'Innate PharmaEU:SANSanofi
      12/18/20233:59PMGlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares - November 2023EU:SANSanofi
      12/18/20233:59PMGlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2023EU:SANSanofi
      12/15/20232:12AMDow Jones NewsSanofi: nouvel avis positif de l'EMA pour le fexinidazole contre la maladie du sommeilEU:SANSanofi
      12/15/20232:07AMDow Jones NewsSanofi: nouvel avis positif de l'EMA pour le fexinidazole contre la maladie du sommeilEU:SANSanofi
      12/15/20231:30AMGlobeNewswire Inc.Communiqué de presse : Mise en ligne du document «Q4 2023 Memorandum for modelling purposes»EU:SANSanofi
       Showing the most relevant articles for your search:EU:SAN